Sep 13, 2022

Featuring an interview with Dr Charles Powell, including the following topics:

• Role of the pulmonologist in the cancer care team; frequency of fatal and Grade 4 interstitial lung disease (ILD) with antibody-drug conjugates (0:00)
• Pathophysiology of pneumonitis associated with checkpoint inhibitors versus antibody-drug conjugates; differences in presentation of ILD based on the cause of disease (8:04)
• Myths and misperceptions about drug-related pneumonitis among general medical oncologists (14:08)
• Monitoring for the onset of ILD using remote technology; typical time to onset of ILD (21:45)
• Risk factors for the development of ILD among patients receiving anticancer therapy (25:58)
• Incidence of ILD with bispecific antibodies; mechanisms underlying differences in the incidence of ILD associated with various antibody-drug conjugates (33:45)

CME information and select publications